These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1750 related articles for article (PubMed ID: 33932192)

  • 1. Brief review of the mRNA vaccines COVID-19.
    Vitiello A; Ferrara F
    Inflammopharmacology; 2021 Jun; 29(3):645-649. PubMed ID: 33932192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 mRNA vaccines.
    Huang Q; Zeng J; Yan J
    J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccines: A race against time.
    Peiffer-Smadja N; Rozencwajg S; Kherabi Y; Yazdanpanah Y; Montravers P
    Anaesth Crit Care Pain Med; 2021 Apr; 40(2):100848. PubMed ID: 33774261
    [No Abstract]   [Full Text] [Related]  

  • 7. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.
    Connors M; Graham BS; Lane HC; Fauci AS
    Ann Intern Med; 2021 May; 174(5):687-690. PubMed ID: 33460347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
    Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
    Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
    [No Abstract]   [Full Text] [Related]  

  • 11. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Key Role of Nucleic Acid Vaccines for One Health.
    Fomsgaard A; Liu MA
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33567520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccines.
    Ndwandwe D; Wiysonge CS
    Curr Opin Immunol; 2021 Aug; 71():111-116. PubMed ID: 34330017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network analysis of COVID-19 mRNA vaccine patents.
    Gaviria M; Kilic B
    Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
    [No Abstract]   [Full Text] [Related]  

  • 16. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.
    Wang AYL
    Cell Transplant; 2022; 31():9636897221090259. PubMed ID: 35438579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
    Pascolo S
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
    Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
    Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.